PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery by Toby M. Maher

Get full text

Chronic hypersensitivity pneumonitis; an enigmatic and frequently fatal disease by Toby M. Maher

Get full text

Recent advances in understanding idiopathic pulmonary fibrosis [version 1; referees: 2 approved] by Cécile Daccord, Toby M. Maher

Get full text

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat by Toby M. Maher, Mary E. Strek

Get full text

The role of infection in the pathogenesis of idiopathic pulmonary fibrosis by Philip L. Molyneaux, Toby M. Maher

Get full text

Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis by Maria Molina-Molina, Maria Molina-Molina, Michael Kreuter, Michael Kreuter, Vincent Cottin, Vincent Cottin, Tamera J. Corte, Tamera J. Corte, Frank Gilberg, Klaus-Uwe Kirchgaessler, Judit Axmann, Toby M. Maher, Toby M. Maher, Toby M. Maher

Get full text

Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis by Toby M. Maher, Christina Schlecker, Doreen Luedtke, Sebastian Bossert, Donald F. Zoz, Armin Schultz

Get full text

Enhanced IL-1β Release Following NLRP3 and AIM2 Inflammasome Stimulation Is Linked to mtROS in Airway Macrophages in Pulmonary Fibrosis by Athina Trachalaki, Athina Trachalaki, Athina Trachalaki, Eliza Tsitoura, Semeli Mastrodimou, Rachele Invernizzi, Eirini Vasarmidi, Eleni Bibaki, Nikolaos Tzanakis, Philip L. Molyneaux, Philip L. Molyneaux, Toby M. Maher, Toby M. Maher, Katerina Antoniou

Get full text

Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era by Gizal Nakshbandi, Catharina C. Moor, Kerri A. Johannson, Toby M. Maher, Michael Kreuter, Marlies S. Wijsenbeek

Get full text

Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial by Michael Kreuter, Elisabeth Bendstrup, Stéphane Jouneau, Toby M. Maher, Yoshikazu Inoue, Corinna Miede, Dirk Lievens, Bruno Crestani

Get full text

Global incidence and prevalence of idiopathic pulmonary fibrosis by Toby M. Maher, Elisabeth Bendstrup, Louis Dron, Jonathan Langley, Gerald Smith, Javaria Mona Khalid, Haridarshan Patel, Michael Kreuter

Get full text

The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease by Anna-Maria Hoffmann-Vold, Yannick Allanore, Elisabeth Bendstrup, Cosimo Bruni, Oliver Distler, Toby M. Maher, Marlies Wijsenbeek, Michael Kreuter

Get full text

Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries by Toby M. Maher, Maria Molina-Molina, Anne-Marie Russell, Francesco Bonella, Stéphane Jouneau, Elena Ripamonti, Judit Axmann, Carlo Vancheri

Get full text

Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects by Toby M. Maher, Arnaud Bourdin, Elizabeth R. Volkmann, Serena Vettori, Jörg H. W. Distler, Margarida Alves, Christian Stock, Oliver Distler

Get full text

Improved quantitation and reproducibility in multi-PET/CT lung studies by combining CT information by Beverley F. Holman, Vesna Cuplov, Lynn Millner, Raymond Endozo, Toby M. Maher, Ashley M. Groves, Brian F. Hutton, Kris Thielemans

Get full text

Autoantibodies are present in the bronchoalveolar lavage but not circulation in patients with fibrotic interstitial lung disease by Karim Boustani, Poonam Ghai, Rachele Invernizzi, Richard J. Hewitt, Toby M. Maher, Quan-Zhen Li, Philip L. Molyneaux, James A. Harker

Get full text

Plain language summary: clinical trial of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis by Luca Richeldi, Arata Azuma, Vincent Cottin, Christian Hesslinger, Susanne Stowasser, Claudia Valenzuela, Marlies S Wijsenbeek, Donald F Zoz, Florian Voss, Toby M Maher

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials by Michael Kreuter, Wim A. Wuyts, Marlies Wijsenbeek, Sabrina Bajwah, Toby M. Maher, Susanne Stowasser, Natalia Male, Wibke Stansen, Nils Schoof, Leticia Orsatti, Jeffrey Swigris

Get full text

Clinical trial simulations in pulmonary fibrosis: patient-focused insights and adaptations by Steve Jones, Maxine Flewett, Ron Flewett, Sharon Lee, Bill Vick, Milla Thompson, Sabine Pinnetti, Donald F. Zoz, Anna-Maria Hoffmann-Vold, Michael Kreuter, Toby M. Maher

Get full text

Effect of Nintedanib on Progression of Systemic Sclerosis‐Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial by Shervin Assassi, Oliver Distler, Yannick Allanore, Takashi Ogura, John Varga, Serena Vettori, Bruno Crestani, Florian Voss, Margarida Alves, Susanne Stowasser, Toby M. Maher, SENSCIS trial investigators

Get full text